Chi Tian-yi, Yang Zhi-ying, Xue Hua-dan, Lü Ke, Feng Rui-e, Xu Hai-feng, Yang Xiao-bo, Sang Xin-ting, Lu Xin, Mao Yi-lei, Zhong Shou-xian, Huang Jie-fu
Department of Liver Surgery, Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhonghua Yi Xue Za Zhi. 2011 Jun 28;91(24):1694-7.
To explore the clinical features, diagnosis, treatment and prognosis of primary hepatic angiosarcoma (PHA).
The clinical data of 7 PHA patients admitted to our hospital from December 2004 to December 2010 were retrospectively analyzed and the relevant literatures reviewed.
Seven cases (5 males and 2 females) were diagnosed as PHA among 1027 (0.68%) patients with primary hepatic malignant tumors. Their mean age was 43.3 years old (range: 33 - 74). Four cases were of solitary lesion and three of multiple lesions. No specific clinical features were observed. The PHA lesions were easily misdiagnosed as benign or hepatic metastatic tumors. Contrast enhanced ultrasound (CEUS) showed the lesions with characteristic manifestations. And the positron emission tomography (PET-CT) could confirm the hepatic lesions as malignant tumors. The survival time for two untreated cases was 3 & 5 months, for two cases with liver transplantation (LTx) 3 & 8 months and for two cases treated with surgical resection & targeted therapy was 14 & 19 months respectively. One case was lost to follow-up at 6 months after hepatic resection.
PHA is a clinically rare and highly malignant tumor with a rapid progression and a poor prognosis. Both CEUS and PET-CT are helpful for its differential and confirmative diagnosis. LTx should be considered as a contraindication for PHA. Hepatic resection has proven to be beneficial for PHA patients with solitary lesion. Surgical resection plus targeted medicines may improve their survival.
探讨原发性肝脏血管肉瘤(PHA)的临床特征、诊断、治疗及预后。
回顾性分析2004年12月至2010年12月我院收治的7例PHA患者的临床资料,并复习相关文献。
在1027例原发性肝脏恶性肿瘤患者中,有7例(5例男性,2例女性)被诊断为PHA,占0.68%。他们的平均年龄为43.3岁(范围:33 - 74岁)。4例为单发病变,3例为多发病变。未观察到特异性临床特征。PHA病变易被误诊为良性或肝脏转移瘤。超声造影(CEUS)显示病变具有特征性表现。正电子发射断层扫描(PET-CT)可确诊肝脏病变为恶性肿瘤。2例未治疗患者的生存时间分别为3个月和5个月,2例肝移植(LTx)患者分别为3个月和8个月,2例接受手术切除及靶向治疗的患者分别为14个月和19个月。1例肝切除术后6个月失访。
PHA是一种临床罕见的高恶性肿瘤,进展迅速,预后较差。CEUS和PET-CT均有助于其鉴别诊断和确诊。LTx应被视为PHA的禁忌证。肝切除已被证明对单发病变的PHA患者有益。手术切除加靶向药物可能改善其生存。